Research & Development
More Diagnostics Inc enters into supply agreement with Emery Pharma
12 April 2018 -

More Diagnostics Inc reported on Wednesday the launch of an agreement for the supply of Liquid Chromatography Mass Spectrometry (LC-MS) services from Emery Pharma.

The four year agreement covers the analysis of the full range of analytes available in the controls for immunoassays used for testing immunosuppressant drugs, including Everolimus, Tacrolimus, Cyclosporine and Sirolimus (Rapamycin), according to the partnership.

Located on the Central Coast of California, More Diagnostics provides immunosuppressant assay controls to diagnostic equipment OEMs, hospitals and laboratories with worldwide distribution channels. It has developed a stable liquid whole-blood Cyclosporine control that became the standard for the industry.

Emery Pharma is an US FDA registered, DEA licensed and cGMP/GLP compliant contract research & development organization focused on supporting mid-size biotech, pharma, synthetic fuel, agro chemistry and novel battery technology and located in Alameda, CA.



Related Headlines